Clinical Trials | April 04, 2024
Evonik unveils latest global trial results MetAMINO
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Subscribe To Our Newsletter & Stay Updated
